XOMA (NASDAQ:XOMA) Upgraded to Hold at StockNews.com

XOMA (NASDAQ:XOMA) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued on Wednesday.

Several other research firms also recently commented on XOMA. SVB Leerink began coverage on XOMA in a report on Monday, April 29th. They issued an “outperform” rating and a $40.00 target price on the stock. HC Wainwright reissued a “buy” rating and issued a $74.00 target price on shares of XOMA in a report on Tuesday, July 9th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of XOMA in a report on Monday, April 29th.

XOMA Stock Down 1.1 %

Shares of XOMA traded down $0.30 on Wednesday, reaching $26.16. The stock had a trading volume of 9,819 shares, compared to its average volume of 20,600. The company has a debt-to-equity ratio of 1.39, a quick ratio of 9.45 and a current ratio of 9.45. XOMA has a 12-month low of $13.48 and a 12-month high of $30.36. The firm has a market capitalization of $304.48 million, a price-to-earnings ratio of -6.67 and a beta of 0.93. The company has a 50-day simple moving average of $25.44 and a 200-day simple moving average of $24.69.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BNP Paribas Financial Markets increased its position in XOMA by 55.6% in the first quarter. BNP Paribas Financial Markets now owns 3,543 shares of the biotechnology company’s stock worth $85,000 after buying an additional 1,266 shares in the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in XOMA during the first quarter valued at approximately $212,000. Bank of New York Mellon Corp raised its position in XOMA by 3.2% during the second quarter. Bank of New York Mellon Corp now owns 62,656 shares of the biotechnology company’s stock valued at $1,484,000 after purchasing an additional 1,968 shares during the period. Finally, Rhumbline Advisers raised its position in XOMA by 16.0% during the second quarter. Rhumbline Advisers now owns 9,695 shares of the biotechnology company’s stock valued at $230,000 after purchasing an additional 1,334 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.